This paper reports that gene-edited, senescence-resistant human mesenchymal progenitor cells (Senescence-Resistant progenitor Cells, SRCs) reduced aging markers across primates, improved cognitive and reproductive function, and exhibited profound rejuvenation effects. SRCs slowed biological aging in diverse organs and tissues far more effectively than conventional cell therapies, and a key finding was that exosomes derived from SRCs mediate these effects. This study provides a critical foundation for prospective human anti-aging treatment strategies.

1. Background and Motivation

Aging triggers the decline of tissue and physiological function, leading to neurodegenerative diseases, reduced fertility, chronic inflammation, cardiovascular disease, and more. Recent research has identified stem cell functional decline and loss of regenerative capacity as core drivers of aging, but whether cell replacement therapies can produce meaningful effects in primates has remained highly debated.

Mesenchymal progenitor cells (MPCs) carry low risk of immune rejection and are already used to treat various conditions, making them a highly attractive target for aging research. However, the aging microenvironment rapidly weakens even these cells' function, necessitating additional senescence resistance.

"The rapid loss of function in transplanted MPCs within the aging environment has been a key limitation of current regenerative medicine."

2. Development and Characteristics of Senescence-Resistant SRCs

The research team performed precision gene editing targeting the longevity gene FOXO3, substituting phosphorylation sites on the FOXO3 protein with amino acid replacements (S253A/S315A) in human embryonic stem cells (hESCs). The MPCs derived from these cells were named SRCs.

SRCs demonstrated:

• Reduced senescence markers (e.g., SA-beta-Gal, IL-6, IL-8)
• Telomere elongation and increased genomic stability
• Enhanced resistance to cellular stress (oxidation, UV, etc.)
• No tumor formation after transplantation
• Maintained core stem cell characteristics and differentiation capacity

These traits made them far more robust in aging environments than conventional MPCs.

"FOXO3-activated SRCs demonstrated outstanding growth capacity, stress resistance, and safety in long-term in vitro and in vivo testing."

3. SRC Treatment Effects in Primates (Macaques)

3.1 Safety and Basic Physical Impact

Over 44 weeks, elderly monkeys (Group A4, equivalent to human ages 57-69) received biweekly intravenous infusions (SRC, standard MPC, or control). Key health indicators -- body temperature, white blood cell count, blood sugar, and weight -- showed no changes, and no tumors or notable side effects were observed.

3.2 Improvements in Cognition, Bone, and Other Aging Markers

• Memory improvement: In delayed memory tests, only the SRC treatment group showed significantly higher accuracy compared to controls.

  "Monkeys that received SRC treatment located food far more accurately even after a 3-second delay."

• Brain structure and neural connectivity: MRI analysis confirmed maintained cortical thickness and volume, increased hippocampal connectivity, and suppressed myelin (a neural insulator critical for brain function) loss.

• Bone density and dental loss improvement: Micro-CT analysis showed that the SRC group exhibited clear reversal of age-related alveolar bone loss and structural deterioration.

4. Blood, Multi-Organ Aging, and Genome-Level Effects

4.1 PBMC (Peripheral Blood Mononuclear Cell) Reprogramming

• Single-cell transcriptomic analysis showed that SRCs reversed a significant portion of aging-related gene expression patterns toward rejuvenation (38.8% of aging-related genes restored).
• Inflammation, senescence, and apoptosis signaling decreased / DNA repair, autophagy, and lymphocyte differentiation increased.

"SRCs turned back the genetic aging clock of overall PBMCs by more than 3 years."

4.2 Multi-Organ Transcriptome/Epigenome Transformation

• Across 61 tissues spanning 10 systems -- including brain, muscle, bone, lung, skin, and reproductive organs -- aging-related transcriptome/methylation clocks showed rejuvenation effects (SRCs delayed aging progression by an average of 3.34 years; WTC by 2.80 years).
• Reproductive organs (female: ovaries; male: testes) showed the most dramatic rejuvenation from SRC treatment.
• Tissues with the greatest SRC-driven aging reversal: hippocampus, prefrontal cortex, reproductive organs, and colon.

4.3 Tissue-Level Aging Improvement

• Across major organs throughout the body, researchers confirmed reduced senescent, inflammatory, and apoptotic cells; restored nuclear structure and heterochromatin; and enhanced tissue regenerative capacity.

  "SRC treatment significantly reversed chronic inflammation, fibrosis, neurodegeneration, and bone loss commonly found in aging tissues."

5. Pronounced Rejuvenation and Functional Improvement of Brain and Reproductive Systems

5.1 Brain Aging, Particularly Hippocampal Rejuvenation

• Single-nucleus RNA-seq results showed aging clock reversal of approximately 2-7 years across immature and mature neurons, glia, and myelin cells.
• Amyloid, tau, and inflammatory response markers decreased, and neurite and synapse distribution improved -- indicating broad brain rejuvenation.

5.2 Suppression of Reproductive Organ Aging in Ovaries and Testes

• In both females and males, biological age of reproductive organs was markedly reversed (notably, oocytes, macrophages, and granulosa cells within ovaries were rejuvenated by 5-7 years).
• Stem cell counts in ovaries and testes recovered; inflammation, oxidative stress, and apoptosis decreased; fertility-related markers improved.

"SRCs reversed cellular and tissue-level changes in aging ovaries and testes to levels nearly equivalent to young tissue."

6. The Role of SRC Exosomes: Core Mechanism of Senescence Resistance

• The powerful effects of SRCs are based on paracrine signaling through exosomes: SRC-derived exosomes are rich in antioxidant, anti-inflammatory, regenerative, and anti-aging substances, and exosome administration alone suppressed biological aging in both mice and human cells.
• SRC exosomes demonstrated robust suppression of aging markers and functional recovery in both live organisms (mice) and in vitro human cells.

"SRC exosomes improved tissue aging markers as significantly as stem cell administration itself."

7. Significance, Limitations, and Future Outlook

Significance

• SRCs provided the first proof in primates (the closest model to humans) that the overall aging clock of diverse organs and tissues can be substantially delayed and reversed.
• Even hard-to-rejuvenate tissues like the brain and reproductive organs were effectively rejuvenated.
• Safety and low immunogenicity were confirmed, laying the groundwork for future clinical application as a universal cell therapy.

Limitations and Future Directions

"Our research provides the first evidence that SRCs can systemically slow primate aging, but long-term functional outcomes and fertility improvements will require additional follow-up studies."

• Future human clinical trials, long-term safety and efficacy assessments, and exploration of mechanisms beyond exosomes are essential.

Conclusion

SRC treatment broadly reduced aging markers across all organs of elderly primates and produced clear functional recovery even in the most difficult-to-rejuvenate areas, such as the brain and reproductive system. Through follow-up research including exosome-based therapies, a comprehensive and fundamental approach to the complex health problem of aging is expected to become feasible. This study represents a decisive milestone demonstrating the potential for a paradigm shift in future human anti-aging treatment.